The analysis, led by Kagan E. Karakus from the Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, and colleagues, explored how semaglutide influences insulin requirements in adults with type 1 diabetes (T1D) and obesity who were using automated insulin delivery systems. While glucagon-like peptide-1 (GLP-1) receptor agonists are not traditionally used in T1D, growing interest surrounds their potential role as adjunct therapies, particularly for patients with obesity and high insulin needs.
The ADJUST-T1D trial was a double-blind, multicenter, randomized, placebo-controlled study evaluating semaglutide 1 mg administered once weekly. In this post hoc analysis, the researchers specifically examined changes in total daily insulin dose, basal and bolus insulin requirements, carbohydrate intake, and the frequency of user-initiated insulin boluses over 26 weeks. Advanced statistical models were used to compare outcomes between the semaglutide and placebo groups, and mediation analyses were performed to distinguish the direct effects of the drug from those related to weight loss.
The study led to the following notable findings:
- Participants receiving semaglutide experienced a substantial and clinically meaningful reduction in overall insulin requirements.
- By 26 weeks, total daily insulin dose decreased by 22.6% compared with baseline.
- The reduction in insulin use was predominantly driven by a decline in bolus insulin rather than basal insulin.
- Bolus insulin requirements fell by more than 30%, while basal insulin doses declined by about 16%.
- The proportion of basal insulin relative to total daily insulin increased, reflecting a shift in insulin dosing patterns.
- Weight-adjusted insulin dose showed a significant decrease over the study period.
- The insulin-sparing effect of semaglutide emerged early, with significant reductions evident as early as four weeks.
- At week 4, most of the insulin dose reduction was attributed to the direct pharmacological effect of semaglutide rather than weight loss.
- By week 26, weight loss accounted for nearly half of the observed reduction in insulin requirements.
- These findings indicate that semaglutide provides both immediate and longer-term benefits through distinct mechanisms.
- Participants treated with semaglutide reported a reduction in daily carbohydrate intake by the end of the study.
- Fewer user-initiated insulin boluses were recorded at all follow-up time points.
- The decrease in bolus frequency suggests reduced need for corrective dosing and potentially improved glycemic stability.
The authors conclude that semaglutide leads to rapid, sustained, and predominantly bolus-driven reductions in insulin requirements in adults with T1D and obesity using automated insulin delivery systems. Early effects appear largely independent of weight loss, highlighting a direct action of the drug on insulin needs. These findings support further investigation into the role of GLP-1 receptor agonists as adjunctive therapies in carefully selected individuals with type 1 diabetes.
Reference:
Kagan E. Karakus, Halis K. Akturk, Davida Kruger, Andrew Ahmann, Anuj Bharvaga, Christine R. Langel, Courtney A. Ackeifi, Jonathan Rosen, Laura Pyle, Janet K. Snell-Bergeon, Viral N. Shah; Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis. Diabetes Care 2025; dc252249. https://doi.org/10.2337/dc25-2249
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.